NYSE:ABBVBiotechs
Could Atogepant Trial Win Change The Bull Case For AbbVie Stock (ABBV)?
AbbVie reported that atogepant reduced menstrual migraine days by 0.80 more days than placebo in the Phase 3 LUNA trial, meeting the primary and all ranked secondary endpoints in adults.
The targeted seven day dosing window around menstruation suggests AbbVie may be able to position atogepant as a focused, intermittent prevention option within its broader neuroscience portfolio.
We will now assess how AbbVie’s broad earnings narrative could shift if intermittent atogepant use expands its...